Back to Search Start Over

Anticancerous plasma-electro-chemotherapy: first in-vivo studies

Authors :
Chung, Thai-Hoa
SKLIAS, Kyriakos
Stancampiano, Augusto
Gazeli, kristaq
Darny, Thibault
André, Franck
Dozias, Sebastien
Douat, Claire
Pouvesle, Jean-Michel
Sousa, Joao Santos
Eric, Robert
Mir, Luis
Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques (METSY)
Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)
Laboratoire de physique des gaz et des plasmas (LPGP)
Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)
Groupe de recherches sur l'énergétique des milieux ionisés (GREMI)
Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
PLASCANCER project (INCa-PlanCancer n◦17CP087-00)
GDR 2025 HAPPYBIO
ZIK plasmatis
ONKOTHER-H
MDPI
Source :
Therapeutic ROS and Immunity in Cancer—The TRIC-21, Therapeutic ROS and Immunity in Cancer—The TRIC-21, ZIK plasmatis; ONKOTHER-H, Jul 2021, Greifswald, Germany. pp.16
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

International audience; Following in vitro assessment of cancer cells and the benefit of a combined treatment based on incubation with plasma treated solution and application of Pulsed Electric Field in the context of reversible cell membrane permeabilization, this work reports on the in vivo evaluation of such combined innovative antitumor approach. Three independent studies, dealing with immunocompetent mice bearing fibrosarcoma tumors and involving control groups, PEF treated group (Bleomycine Electro Chemo Therapy (ECT) and combined plasma treated PBS (p-PBS) and PEF treatments, were performed. A single-shot treatment was applied 12 days after tumor cell injection, and follow up of tumor volume was performed for more than two months. The main conclusions of these studies indicate that (i) p-PBS production and storage was highly reproducible and allow for in vivo studies requiring large volume of such solutions; (ii) Bleomycin, p-PBS, and their combined injection has no antitumor action; (iii) ECT as a reference therapy is efficient, especially for fast growing tumors; (iv) combined p-PBS and ECT treatment allow for a slower tumor growthrate, for fast growing tumors, and lead to a significant increase of the number of tumor regressions; and (v) composition of p-PBS solution for different plasma exposures might be a unique parameter for a fine tuning of the efficiency of the combined antitumor treatment.

Details

Language :
English
Database :
OpenAIRE
Journal :
Therapeutic ROS and Immunity in Cancer—The TRIC-21, Therapeutic ROS and Immunity in Cancer—The TRIC-21, ZIK plasmatis; ONKOTHER-H, Jul 2021, Greifswald, Germany. pp.16
Accession number :
edsair.dedup.wf.001..d2c4f30aeea64ac6377c913b82073b3b